Correlation between CD4 Count and Dental Caries in HIV-seropositive Children Undergoing Antiretroviral Therapy

Background: Detection of Hepatitis B surface antibodies (anti-HBs) in the serum implies that an individual is immune to HBV infection either from vaccination or past infection, which usually persists for life. Aim: This study was aimed to determine the seropositivity of anti-HBs among HIV-seropositive patients and further appraise the effect of co-infection on their immunological status in Ojo, Lagos. Materials and Methods: A total of 74 blood samples collected from HIV positive patients were analysed for anti-HBs (HBsAb) by Immunochromatographic assay (Biotec, UK). CD4+ count was determined using BD FACS Count Automated analyser. Results: Out of the 74 HIV infected patients screened, 12 (16.2 %) males and 62 (83.8 %) females, 2 patients (2.7 %) were positive for anti-HBs, with no prevalence among the males and 2.7 % among the females. Anti-HBs was only recorded in HIV positive patients in the 21-30 years age group (8.7 %). The result showed anti-HBs lifelong protection to HBV among HIV patients with CD4+ Count ranging from 601-700 and 901-1000 to be 1.7 % and 1.7 % respectively. Protection of 3.5 % was reported among antiretroviral therapy (ART) naïve patients and 0 % protection among ART patients. Conclusions: Our findings showed prevalence of 2.7% HBsAb in the studied HIV positive patients with a protection of 3.5 % anti-HBs to HBV among antiretroviral therapy (ART) naïve patients in Ojo, Lagos. The low prevalence of HBsAb in HIV positive patients may be attributed to suppression of immune responses leading to the loss of previously developed protective antibody against HBV infection. We hereby suggest anti-HBs screening for all HIV positive patients and that those negative should be vaccinated to help them develop protective immunity to HBV infection.

Download Full-text

Correlation of CD4 Count with Dental caries in HIV Seropositive Individuals with and without ART (Anti Retroviral Therapy)

Journal of Health & Medical Informatics ◽

10.4172/scientificreports.442 ◽

2012 ◽

Vol 01 (09) ◽

Cited By ~ 1

Author(s):

Venkatesh Kasiraj Gandhiraj

Keyword(s):

Dental Caries ◽

Cd4 Count ◽

Hiv Seropositive

Download Full-text

Faculty Opinions recommendation of Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14037964.15498068 ◽

2012 ◽

Author(s):

Suzanne Dawid ◽

Nurul Hariadi

Keyword(s):

T Cell ◽

Antiretroviral Therapy ◽

Cd4 Count ◽

T Cell Reconstitution

Download Full-text

Hematological Profile of HIV-Infected Patients on First-Line Highly Active Antiretroviral Therapy and Its Correlation With CD4 Count

International Journal of Recent Surgical and Medical Sciences ◽

10.1055/s-0041-1730257 ◽

2021 ◽

Author(s):

John Jospeh Diamond Princy ◽

Kshetrimayum Birendra Singh ◽

Ningthoujam Biplab ◽

Ningthoukhongjam Reema ◽

Rajesh Boini ◽

...

Keyword(s):

Platelet Count ◽

Antiretroviral Therapy ◽

Hiv Infection ◽

Highly Active Antiretroviral Therapy ◽

Cd4 Count ◽

Total Leukocyte Count ◽

Hiv Patients ◽

Positive Correlation ◽

Highly Active ◽

The Mean

Abstract Introduction Human immunodeficiency virus (HIV) infection is a state of profound immunodeficiency. Disorders of hematopoietic system are a common but often overlooked complication of HIV infection. This can manifest at any stage of the disease but more commonly in the advanced stage with low CD4 count. Anemia is the most common hematological abnormality in HIV patients and prevalence ranges from 1.3 to 95%. As HIV disease progresses, the prevalence and severity of anemia also increase. Hence, this study was undertaken to assess the hematological parameters of HIV-infected patients on highly active antiretroviral therapy (HAART) at different treatment durations with the hope to improve the HAART outcome in HIV patients and its correlation with CD4 count. Methods This prospective longitudinal study enrolled 134 HIV-infected patients admitted to or attending the OPD in the Department of Medicine or Antiretroviral Therapy (ART) Center (Center of Excellence), Regional Institute of Medical Sciences (RIMS), Imphal, Manipur, from 2018 to 2020. Complete hemogram, CD4 count, and other related-blood investigations were studied. Results The mean age of the study population was 39.9 ± 11.04 years. Of the 134 patients, 75 (56%) were males and 59 (44%) were females. Twelve (9%) patients had a history of injecting drug use (IDU). TLE (tenofovir, lamivudine, efavirenz) regimen was started on 112 (83.6%) patients and the majority of them (69/134 [51.5%]) had a CD4 count of 200 to 499 cells/mm3, which increased significantly 6 months after HAART to 99 to 1,149 cells/mm3, with a mean of 445 ± 217 cells/mm3. There were significant improvements in hemoglobin (Hb) levels, total leukocyte count (TLC), absolute neutrophil count (ANC), and absolute lymphocyte count (ALC) after HAART indicating a positive correlation with CD4 count (p < 0.05). Thrombocytopenia was observed higher after HAART when compared to baseline. There was a positive correlation between platelet count and CD4 count. However, the mean corpuscular volume (MCV) and erythrocyte sedimentation rate (ESR) had a negative correlation with CD4 count. Conclusion The study inferred a strong positive correlation between CD4 and Hb levels, TLC, ANC, ALC, and platelet count after HAART with improvement in these values as CD4 count increases. Specific treatment intervention based on the changes in the immunohematological profile trends can help prevent most of the adverse effects on HIV patients in our community.

Download Full-text

Estimates of the Time From Seroconversion to Antiretroviral Therapy Initiation Among People Newly Diagnosed With Human Immunodeficiency Virus From 2006 to 2015, New York City

Clinical Infectious Diseases ◽

10.1093/cid/ciz1178 ◽

2019 ◽

Vol 71 (8) ◽

pp. e308-e315

Author(s):

McKaylee M Robertson ◽

Sarah L Braunstein ◽

Donald R Hoover ◽

Sheng Li ◽

Denis Nash

Keyword(s):

Human Immunodeficiency Virus ◽

Antiretroviral Therapy ◽

Hiv Testing ◽

Mixed Model ◽

Linear Mixed Model ◽

Population Based ◽

Cd4 Count ◽

Hiv Diagnosis ◽

Art Initiation ◽

Immunodeficiency Virus

Abstract Background We estimated the time from human immunodeficiency virus (HIV) seroconversion to antiretroviral therapy (ART) initiation during an era of expanding HIV testing and treatment efforts. Methods Applying CD4 depletion parameters from seroconverter cohort data to our population-based sample, we related the square root of the first pretreatment CD4 count to time of seroconversion through a linear mixed model and estimated the time from seroconversion. Results Among 28 162 people diagnosed with HIV during 2006–2015, 89% initiated ART by June 2017. The median CD4 count at diagnosis increased from 326 (interquartile range [IQR], 132–504) cells/µL to 390 (IQR, 216–571) cells/µL from 2006 to 2015. The median time from estimated seroconversion to ART initiation decreased by 42% from 6.4 (IQR, 3.3–11.4) years in 2006 to 3.7 (IQR, 0.5–8.3) years in 2015. The time from estimated seroconversion to diagnosis decreased by 28%, from a median of 4.6 (IQR, 0.5–10.5) years to 3.3 (IQR, 0–8.1) years from 2006 to 2015, and the time from diagnosis to ART initiation reduced by 60%, from a median of 0.5 (IQR, 0.2–2.1) years to 0.2 (IQR, 0.1–0.3) years from 2006 to 2015. Conclusions The estimated time from seroconversion to ART initiation was reduced in tandem with expanded HIV testing and treatment efforts. While the time from diagnosis to ART initiation decreased to 0.2 years, the time from seroconversion to diagnosis was 3.3 years among people diagnosed in 2015, highlighting the need for more effective strategies for earlier HIV diagnosis.

Download Full-text